Vistagen Therapeutics Inc
VTGN4.020USD
-0.160-3.83%
收盤 11/06, 16:00（美東）報價延遲15分鐘
117.71M總市值
虧損本益比TTM
關於 Vistagen Therapeutics Inc 公司
Vistagen Therapeutics, Inc. 是一家專注於神經科學的生物製藥公司。該公司基於對鼻腦神經迴路的理解，致力於開發和商業化治療精神和神經疾病的療法。其臨牀階段產品線包括一種新型潛在神經科學療法（稱爲 pherines）的鼻內產品候選物。其多樣化的 pherine 產品候選物產品線可快速激活鼻腔中的化學感應神經元，從而影響嗅覺系統和大腦中的基本神經迴路。其產品線還包括一種口服前藥，具有調節 N-甲基-D-天冬氨酸受體 (NMDA) 受體活性的潛力。其神經科學產品線包括五種臨牀階段研究藥物，即 Fasedienol (PH94B)、Itruvone (PH10)、AV-101、PH15、PH80 和 PH284。
Vistagen Therapeutics Inc簡介
公司代碼VTGN
公司名稱Vistagen Therapeutics Inc
上市日期Oct 18, 2010
CEOMr. Shawn K. Singh, J.D.
員工數量56
證券類型Ordinary Share
年結日Oct 18
公司地址343 Allerton Avenue
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編94080
電話16505773600
網址https://www.vistagen.com/
公司代碼VTGN
上市日期Oct 18, 2010
CEOMr. Shawn K. Singh, J.D.
Vistagen Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Shawn K. Singh, J.D.
Mr. Shawn K. Singh, J.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
38.90K
--
Mr. Joshua S Prince
Mr. Joshua S Prince
Chief Operating Officer
Chief Operating Officer
10.86K
--
Mr. Jon S. Saxe, J.D.
Mr. Jon S. Saxe, J.D.
Independent Director
Independent Director
1.86K
--
Mr. Reid G. Adler, J.D.
Mr. Reid G. Adler, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Margaret M. (Maggie) Fitzpatrick
Ms. Margaret M. (Maggie) Fitzpatrick
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Mary L. Rotunno
Ms. Mary L. Rotunno
Independent Director
Independent Director
--
--
Dr. Joanne Curley, Ph.D.
Dr. Joanne Curley, Ph.D.
Independent Director
Independent Director
--
--
Ms. Elissa Cote
Ms. Elissa Cote
Chief Corporate Development Officer
Chief Corporate Development Officer
--
--
Ms. Ann Michelle Cunningham
Ms. Ann Michelle Cunningham
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Mark A. Mcpartland
Mr. Mark A. Mcpartland
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Shawn K. Singh, J.D.
Mr. Shawn K. Singh, J.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
38.90K
--
Mr. Joshua S Prince
Mr. Joshua S Prince
Chief Operating Officer
Chief Operating Officer
10.86K
--
Mr. Jon S. Saxe, J.D.
Mr. Jon S. Saxe, J.D.
Independent Director
Independent Director
1.86K
--
Mr. Reid G. Adler, J.D.
Mr. Reid G. Adler, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Margaret M. (Maggie) Fitzpatrick
Ms. Margaret M. (Maggie) Fitzpatrick
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Mary L. Rotunno
Ms. Mary L. Rotunno
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 9月13日 週六
更新時間: 9月13日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Janus Henderson Investors
13.95%
TCG Crossover Management, LLC
8.96%
Nantahala Capital Management, LLC
6.63%
StemPoint Capital LP
6.02%
The Vanguard Group, Inc.
5.65%
其他
58.79%
持股股東
持股股東
佔比
Janus Henderson Investors
13.95%
TCG Crossover Management, LLC
8.96%
Nantahala Capital Management, LLC
6.63%
StemPoint Capital LP
6.02%
The Vanguard Group, Inc.
5.65%
其他
58.79%
股東類型
持股股東
佔比
Investment Advisor
25.24%
Hedge Fund
19.02%
Investment Advisor/Hedge Fund
16.23%
Research Firm
3.38%
Individual Investor
0.34%
其他
35.79%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
105
19.07M
63.87%
-1.31M
2025Q2
119
15.55M
52.09%
-4.48M
2025Q1
178
15.52M
53.23%
-4.54M
2024Q4
189
15.27M
53.10%
-1.38M
2024Q3
188
15.00M
55.60%
-3.08M
2024Q2
215
16.08M
59.60%
-5.25M
2024Q1
231
17.00M
63.09%
-4.65M
2023Q4
242
17.28M
64.17%
+1.95M
2023Q3
236
3.11M
33.43%
-2.83M
2023Q2
238
1.09M
13.89%
-3.94M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Janus Henderson Investors
4.17M
13.95%
+4.17M
--
Aug 29, 2025
TCG Crossover Management, LLC
2.68M
8.96%
--
--
Jun 30, 2025
Nantahala Capital Management, LLC
1.98M
6.63%
--
--
Jun 30, 2025
StemPoint Capital LP
1.80M
6.02%
+46.70K
+2.67%
Jun 30, 2025
The Vanguard Group, Inc.
1.76M
5.89%
-200.53K
-10.23%
Jun 30, 2025
Commodore Capital LP
1.57M
5.27%
--
--
Jun 30, 2025
J.P. Morgan Securities LLC
748.85K
2.51%
-2.01K
-0.27%
Jun 30, 2025
Ikarian Capital LLC
601.70K
2.02%
--
--
Jun 30, 2025
Sphera Funds Management Ltd.
447.94K
1.5%
-342.61K
-43.34%
Jun 30, 2025
Adar1 Capital Management LLC
420.76K
1.41%
--
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 13 小時前
更新時間: 13 小時前
機構名稱
佔比
AdvisorShares Psychedelics ETF
5.35%
iShares Micro-Cap ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
iShares Neuroscience and Healthcare ETF
0%
AdvisorShares Psychedelics ETF
佔比5.35%
iShares Micro-Cap ETF
佔比0.02%
Avantis US Small Cap Equity ETF
佔比0.01%
iShares Neuroscience and Healthcare ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
公告日期
類型
比率
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
